{
  "id": 10992913,
  "title": "Braveheart at Stifel cardiometabolic forum: cash-rich push in HCM",
  "url": "https://urgent.news/2026/09/30/braveheart-at-stifel-cardiometabolic-forum-cash-rich-push-in-hcm",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T17:11:48.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/braveheart-at-stifel-cardiometabolic-forum-cashrich-push-in-hcm-93CH-4925649"
  },
  "original_language": "en",
  "account": "On September 30th, 2026, Braveheart (BRVE) utilized the Stifel 2026 Virtual Cardiometabolic Forum to announce an aggressive strategy for hypertrophic cardiomyopathy (HCM). The company disclosed that it had approximately $500 million in cash reserves, with adjusted cash exceeding $520 million following its IPO. The focal point of Braveheart's presentation was their lead drug, BHB-1893, which is undergoing Phase III trials for both obstructive and non-obstructive HCM.\n\nManagement highlighted that BHB-1893 could potentially offer superior efficacy, fewer safety restrictions, and simplified monitoring compared to current cardiac myosin inhibitors. Early data from China and Braveheart's own studies revealed rapid gradient reductions, biomarker improvements, and minimal impact on ejection fraction. The company is confident that the FDA will likely approve an early filing strategy, combining interim U.S. data with comprehensive Chinese Phase III results.\n\nChief Financial Officer Paul Rickey confirmed that Braveheart's adjusted cash balance, inclusive of IPO proceeds, exceeded $520 million. The financing was earmarked to support both Phase III programs, LIONHEART-HCM and NOBLEHEART-HCM, through data readouts and early pre-launch planning. Braveheart was established in 2023, rapidly transforming into a company with a balance sheet of around $500 million.\n\nThe firm is targeting patients with HCM and related conditions, an industry they describe as substantial and unexplored. Management aims to distinguish themselves from existing cardiac myosin inhibitors, such as mavacamten and aficamten, by targeting better efficacy, a greater safety margin, and easier administration for physicians. Despite being unprofitable, with a loss of $14.68 per share in the past year, Braveheart is heavily investing in clinical development. They recognize the market is transitioning from focusing on new patient starts to prevalent patient starts, with non-obstructive HCM identified as a significant area of unmet need.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Inventiva at Stifel cardiometabolic forum: lanifibranor nears key test",
        "url": "https://urgent.news/2026/09/30/inventiva-at-stifel-cardiometabolic-forum-lanifibranor-nears-key-test",
        "published": "2026-09-30T13:11:02.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}